Lin Bioscience (6696.TWO) Akcija Kursas

Lin Bioscience Inc, listed on the Taiwan Stock Exchange with ticker 6696.TWO, is headquartered in Taipei City, Taiwan. The company operates in the Health Care sector within the Biotechnology industry. Lin Bioscience went public via an IPO on October 8, 2018. It is engaged in drug development, focusing on research and clinical trials. The company has four drugs in development: LBS-008, LBS-007, LBS-009, and LBS-002, alongside two technical platforms, RBP4 and CDC7. LBS-008 targets dry macular degeneration and stel lesions; LBS-007 addresses acute leukemia and solid tumors; LBS-009 focuses on NAFLD, NASH, and type 2 diabetes; LBS-002 is for primary and metastatic brain cancer. The RBP4 platform targets metabolic diseases, and CDC7 targets all cancers.